David joined the T1D Fund in 2019 and serves as an Entrepreneur-in-Residence to help build and invest in companies addressing the needs of patients with T1D and other serious diseases.
David is an experienced advisor and consultant in the life sciences industry, and was most recently Vice President at the venture creation firm, PureTech Health (LON: PRTC), where he held multiple business development and C-level operational roles for its portfolio companies. Prior to this role, he led evaluation and diligence of US licensing and M&A opportunities in neurology, endocrinology, oncology, and other specialty areas at the biopharmaceutical division of Merck KGaA. Earlier in his career, David held leadership positions in business development and consulting, and contributed to several academic and corporate research projects including an appointment as visiting scientist at the Whitehead Institute/MIT Center for Genome Research.
David completed his B.S. in Biological Sciences at the University of Massachusetts Amherst and received his M.B.A. from the Saïd Business School at the University of Oxford in the UK.